Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity : a pilot study
© 2021. Springer-Verlag Italia S.r.l., part of Springer Nature..
AIMS: To identify fecal microbiota profiles associated with metabolic abnormalities belonging to the metabolic syndrome (MS), high count of white blood cells (WBCs) and insulin resistance (IR).
METHODS: Sixty-eight young patients with obesity were stratified for percentile distribution of MS abnormalities. A MS risk score was defined as low, medium, and high MS risk. High WBCs were defined as a count ≥ 7.0 103/µL; severe obesity as body mass index Z-score ≥ 2 standard deviations; IR as homeostatic assessment model algorithm of IR (HOMA) ≥ 3.7. Stool samples were analyzed by 16S rRNA-based metagenomics.
RESULTS: We found reduced bacterial richness of fecal microbiota in patients with IR and high diastolic blood pressure (BP). Distinct microbial markers were associated to high BP (Clostridium and Clostridiaceae), low high-density lipoprotein cholesterol (Lachnospiraceae, Gemellaceae, Turicibacter), and high MS risk (Coriobacteriaceae), WBCs (Bacteroides caccae, Gemellaceae), severe obesity (Lachnospiraceae), and impaired glucose tolerance (Bacteroides ovatus and Enterobacteriaceae). Conversely, taxa such as Faecalibacterium prausnitzii, Parabacterodes, Bacteroides caccae, Oscillospira, Parabacterodes distasonis, Coprococcus, and Haemophilus parainfluenzae were associated to low MS risk score, triglycerides, fasting glucose and HOMA-IR, respectively. Supervised multilevel analysis grouped clearly "variable" patients based on the MS risk.
CONCLUSIONS: This was a proof-of-concept study opening the way at the identification of fecal microbiota signatures, precisely associated with cardiometabolic risk factors in young patients with obesity. These evidences led us to infer, while some gut bacteria have a detrimental role in exacerbating metabolic risk factors some others are beneficial ameliorating cardiovascular host health.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Acta diabetologica - 58(2021), 8 vom: 18. Aug., Seite 1009-1022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Del Chierico, Federica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 16.07.2021 Date Revised 16.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00592-020-01669-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323104630 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323104630 | ||
| 003 | DE-627 | ||
| 005 | 20231225183443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00592-020-01669-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM323104630 | ||
| 035 | |a (NLM)33754165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Del Chierico, Federica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity |b a pilot study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2021 | ||
| 500 | |a Date Revised 16.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Springer-Verlag Italia S.r.l., part of Springer Nature. | ||
| 520 | |a AIMS: To identify fecal microbiota profiles associated with metabolic abnormalities belonging to the metabolic syndrome (MS), high count of white blood cells (WBCs) and insulin resistance (IR) | ||
| 520 | |a METHODS: Sixty-eight young patients with obesity were stratified for percentile distribution of MS abnormalities. A MS risk score was defined as low, medium, and high MS risk. High WBCs were defined as a count ≥ 7.0 103/µL; severe obesity as body mass index Z-score ≥ 2 standard deviations; IR as homeostatic assessment model algorithm of IR (HOMA) ≥ 3.7. Stool samples were analyzed by 16S rRNA-based metagenomics | ||
| 520 | |a RESULTS: We found reduced bacterial richness of fecal microbiota in patients with IR and high diastolic blood pressure (BP). Distinct microbial markers were associated to high BP (Clostridium and Clostridiaceae), low high-density lipoprotein cholesterol (Lachnospiraceae, Gemellaceae, Turicibacter), and high MS risk (Coriobacteriaceae), WBCs (Bacteroides caccae, Gemellaceae), severe obesity (Lachnospiraceae), and impaired glucose tolerance (Bacteroides ovatus and Enterobacteriaceae). Conversely, taxa such as Faecalibacterium prausnitzii, Parabacterodes, Bacteroides caccae, Oscillospira, Parabacterodes distasonis, Coprococcus, and Haemophilus parainfluenzae were associated to low MS risk score, triglycerides, fasting glucose and HOMA-IR, respectively. Supervised multilevel analysis grouped clearly "variable" patients based on the MS risk | ||
| 520 | |a CONCLUSIONS: This was a proof-of-concept study opening the way at the identification of fecal microbiota signatures, precisely associated with cardiometabolic risk factors in young patients with obesity. These evidences led us to infer, while some gut bacteria have a detrimental role in exacerbating metabolic risk factors some others are beneficial ameliorating cardiovascular host health | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Insulin resistance | |
| 650 | 4 | |a Low-grade inflammation | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Obesity | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 700 | 1 | |a Manco, Melania |e verfasserin |4 aut | |
| 700 | 1 | |a Gardini, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Guarrasi, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Tortosa, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Quagliariello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Shashaj, Blegina |e verfasserin |4 aut | |
| 700 | 1 | |a Fintini, Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Putignani, Lorenza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta diabetologica |d 1997 |g 58(2021), 8 vom: 18. Aug., Seite 1009-1022 |w (DE-627)NLM012966797 |x 1432-5233 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2021 |g number:8 |g day:18 |g month:08 |g pages:1009-1022 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00592-020-01669-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2021 |e 8 |b 18 |c 08 |h 1009-1022 | ||